{
  "generated": "2025-10-24T08:19:11.390097+00:00",
  "policy_fingerprint": "0x9c4caca78ebe0554",
  "source_evidence": "entries/immune/maitake-imm-imm18/immune/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "IMM-IMM18_01",
      "year": 2015,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "immune_modulation",
      "population": "Adults with immune modulation concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/maitake-imm-imm18-01",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-01",
      "citation": "IMM-IMM18_01 (2015); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with immune modulation concerns; Outcome: immune_modulation; DOI: 10.1234/maitake-imm-imm18-01; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-IMM18_02",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "immune_modulation",
      "population": "Adults with immune modulation concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/maitake-imm-imm18-02",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-02",
      "citation": "IMM-IMM18_02 (2016); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with immune modulation concerns; Outcome: immune_modulation; DOI: 10.1234/maitake-imm-imm18-02; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-IMM18_03",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "immune_modulation",
      "population": "Adults with immune modulation concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/maitake-imm-imm18-03",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-03",
      "citation": "IMM-IMM18_03 (2017); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with immune modulation concerns; Outcome: immune_modulation; DOI: 10.1234/maitake-imm-imm18-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/maitake-imm-imm18-01",
      "study_ids": [
        "IMM-IMM18_01"
      ],
      "primary_study_id": "IMM-IMM18_01",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/maitake-imm-imm18-02",
      "study_ids": [
        "IMM-IMM18_02"
      ],
      "primary_study_id": "IMM-IMM18_02",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/maitake-imm-imm18-03",
      "study_ids": [
        "IMM-IMM18_03"
      ],
      "primary_study_id": "IMM-IMM18_03",
      "url": "https://doi.org/10.1234/maitake-imm-imm18-03"
    }
  ],
  "manifest_hash": "sha256:04adb911bc688542d58ef606785014236d38e1269f7158db2691c57d7e71e268"
}
